Redwood Grove Capital LLC Sells 265,200 Shares of Elanco Animal Health Incorporated $ELAN

Redwood Grove Capital LLC reduced its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 17.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,291,800 shares of the company’s stock after selling 265,200 shares during the quarter. Elanco Animal Health makes up 10.0% of Redwood Grove Capital LLC’s investment portfolio, making the stock its biggest holding. Redwood Grove Capital LLC’s holdings in Elanco Animal Health were worth $30,913,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ELAN. NewEdge Advisors LLC raised its position in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares in the last quarter. Root Financial Partners LLC lifted its stake in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $41,000. Torren Management LLC acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $46,000. Finally, Bessemer Group Inc. boosted its holdings in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on ELAN shares. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen increased their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. JPMorgan Chase & Co. lifted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.73.

Elanco Animal Health Trading Up 0.5%

ELAN opened at $25.53 on Wednesday. The firm has a market cap of $12.75 billion, a price-to-earnings ratio of -51.05, a price-to-earnings-growth ratio of 1.66 and a beta of 1.68. Elanco Animal Health Incorporated has a 52 week low of $13.39 and a 52 week high of $27.72. The business’s 50 day moving average is $24.24 and its two-hundred day moving average is $24.01. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.